Andreas Eckert
Clinical Researcher
Data updated
Papers
Trials
Research Footprint
Andreas Eckert appears in 18 tracked papers (2019–2026), most studied alongside MDMA, LSD and Psilocybin, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Anxiety Disorders.
Most-cited paper: Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. (248 citations).
Frequent co-authors: Matthias Liechti, Nikhil Varghese and Friederike Holze.
Background & Research
Andreas Eckert is a clinical researcher active in experimental human psychopharmacology with a focus on acute-phase studies of classical psychedelics and entactogens. He has co‑authored multiple randomised, double‑blind, placebo‑controlled and crossover trials in healthy volunteers examining the acute subjective, physiological and receptor‑mediated effects of compounds including LSD, psilocybin, DMT and several MDMA variants. His work frequently appears in collaborations that probe dose‑responses, stereoisomer differences, drug–drug interactions (for example SSRI pretreatment) and the role of the 5‑HT2A receptor in mediating acute psychedelic effects.
Key Impact
Notable for contributions to controlled human experimental studies characterising acute effects, pharmacology and receptor mechanisms of serotonergic and entactogenic compounds.
Collaboration Network
26 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Andreas Eckert is associated with.
University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →